Aclaris Therapeutics (ACRS) Capital Expenditures (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Capital Expenditures of $60000.0 for Q1 2026, up 39.53% year-over-year from $43000.0 in Q1 2025, and down 39.39% quarter-over-quarter from $99000.0 in Q4 2025.
Aclaris Therapeutics (ACRS) Capital Expenditures (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Capital Expenditures history runs 13 years deep, the most recent figure standing at $60000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 39.53% year-over-year to $60000.0; the TTM figure through Mar 2026 stood at $128000.0 (up 341.38% YoY), while the FY2025 annual figure was $111000.0, down 8.26% from the prior year.
- Capital Expenditures for Q1 2026 stood at $60000.0, down from $99000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $933000.0 in Q4 2023, with the low at -$476000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $60000.0 (2026), against an average of $108333.3.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 338.0% in 2022, then jumped 296.01% in 2023.
- Aclaris Therapeutics' Capital Expenditures stood at -$476000.0 in 2022, then surged by 296.01% to $933000.0 in 2023, then plunged by 101.5% to -$14000.0 in 2024, then soared by 807.14% to $99000.0 in 2025, then slumped by 39.39% to $60000.0 in 2026.
- Business Quant data shows ACRS's Capital Expenditures at $60000.0 in Q1 2026, $99000.0 in Q4 2025, and -$52000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,000.00 |
| Jun 30, 2026 | 11,000.00 |
| Mar 31, 2026 | 60,000.00 |
| Mar 31, 2026 | 60,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Sep 30, 2025 | -52,000.00 |
| Sep 30, 2025 | -52,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 135,000.00 |
| Mar 31, 2024 | 135,000.00 |
| Dec 31, 2023 | 933,000.00 |
| Dec 31, 2023 | 933,000.00 |
| Sep 30, 2023 | -18,000.00 |
| Sep 30, 2023 | -18,000.00 |